ERBB2 and breast cancer: However, in spite of the international guidelines recommended endocrine-based therapy as a preferred first-line treatment for HR-positive/HER2-negative advanced breast cancer, various studies have reported that 35–60% patients in Europe and North-America received chemotherapy as a first-line therapy, particularly younger patients with visceral disease [507,508,509,510].